|
US7037916B2
(en)
*
|
1999-07-15 |
2006-05-02 |
Pharmacopeia Drug Discovery, Inc. |
Pyrimidine derivatives as IL-8 receptor antagonists
|
|
GB0016877D0
(en)
*
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6867300B2
(en)
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
US20030139435A1
(en)
*
|
2001-06-26 |
2003-07-24 |
Gulzar Ahmed |
N-heterocyclic inhibitors of TNF-alpha expression
|
|
KR20040062557A
(ko)
*
|
2001-11-01 |
2004-07-07 |
얀센 파마슈티카 엔.브이. |
글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
KR101025675B1
(ko)
*
|
2002-04-23 |
2011-03-30 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
|
|
JP2005529890A
(ja)
|
2002-04-23 |
2005-10-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ阻害剤として有用なアリールケトンピロロトリアジン化合物
|
|
ES2445208T3
(es)
*
|
2002-07-29 |
2014-02-28 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
|
|
BR0316680A
(pt)
*
|
2002-11-28 |
2005-10-18 |
Schering Ag |
Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
|
|
US6909001B2
(en)
|
2002-12-12 |
2005-06-21 |
Pharmacia Corporation |
Method of making tricyclic aminocyanopyridine compounds
|
|
WO2004054505A2
(en)
*
|
2002-12-12 |
2004-07-01 |
Pharmacia Corporation |
Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
|
|
WO2004069829A1
(en)
*
|
2003-01-10 |
2004-08-19 |
Pharmacopeia Drug Discovery, Inc. |
(2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis
|
|
SI1599468T1
(sl)
*
|
2003-01-14 |
2008-02-29 |
Arena Pharm Inc |
1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije
|
|
UA92450C2
(ru)
*
|
2003-01-14 |
2010-11-10 |
Арена Фармасьютикалз, Инк. |
1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
|
|
MXPA05007485A
(es)
*
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
BRPI0407282A
(pt)
|
2003-02-05 |
2006-01-31 |
Bristol Myers Squibb Co |
Processo para preparação de inibidores de pirrolotriazina cinase
|
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
DK1618092T3
(da)
*
|
2003-05-01 |
2011-01-31 |
Bristol Myers Squibb Co |
Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
|
|
US7652044B2
(en)
|
2003-06-03 |
2010-01-26 |
Novartis A.G. |
P-38 inhibitors
|
|
WO2004113305A2
(en)
|
2003-06-16 |
2004-12-29 |
Vertex Pharmaceuticals Incorporated |
Diamino substituted quinazoline derivatives as promoters of smn2
|
|
US7504396B2
(en)
*
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
AR045047A1
(es)
*
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
BRPI0413018B8
(pt)
|
2003-07-30 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, e, uso de um composto
|
|
NZ585188A
(en)
*
|
2003-08-15 |
2011-09-30 |
Novartis Ag |
2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
|
PE20050483A1
(es)
|
2003-10-31 |
2005-08-25 |
Arena Pharm Inc |
Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
|
|
CA2545048A1
(en)
*
|
2003-11-20 |
2005-06-02 |
Warner-Lambert Company Llc |
Androgen receptor modulators
|
|
US7459562B2
(en)
*
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
EP1763514A2
(en)
|
2004-05-18 |
2007-03-21 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
|
EA011671B1
(ru)
*
|
2004-06-04 |
2009-04-28 |
Арена Фармасьютикалз, Инк. |
Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
|
|
US7253167B2
(en)
*
|
2004-06-30 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic-heteroaryl compounds useful as kinase inhibitors
|
|
TW200600513A
(en)
*
|
2004-06-30 |
2006-01-01 |
Bristol Myers Squibb Co |
A method for preparing pyrrolotriazine compounds
|
|
US7504521B2
(en)
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
US7148348B2
(en)
|
2004-08-12 |
2006-12-12 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
US7820654B2
(en)
*
|
2004-09-23 |
2010-10-26 |
Dr. Reddy's Laboratories Ltd. |
Pyrimidine compounds, process for their preparation and compositions containing them
|
|
WO2006037117A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
|
EP1814878B1
(en)
|
2004-11-24 |
2012-01-04 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
|
MY148521A
(en)
*
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
US20060247263A1
(en)
*
|
2005-04-19 |
2006-11-02 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
US8278446B2
(en)
*
|
2005-12-21 |
2012-10-02 |
Janssen Pharmaceutica N.V. |
Process for preparing substituted diaminopyrimidine oximes
|
|
WO2007081630A2
(en)
*
|
2005-12-21 |
2007-07-19 |
Janssen Pharmaceutica, N.V. |
Substituted pyrimidinyl kinase inhibitors
|
|
US8153791B2
(en)
*
|
2005-12-21 |
2012-04-10 |
Janssen Pharmaceutica N.V. |
Substituted pyrimidinyl oxime kinase inhibitors
|
|
WO2007109783A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Janssen Pharmaceutica, N.V. |
Substituted pyrimidine kinase inhibitors
|
|
EP2046763A2
(en)
|
2006-07-31 |
2009-04-15 |
Praecis Pharmaceuticals Incorporated |
Aurora kinase inhibitors from an encoded small molecule library
|
|
JP2009545598A
(ja)
*
|
2006-08-01 |
2009-12-24 |
プリーシス・ファーマシューティカルズ・インコーポレイテッド |
Ｐ３８キナーゼ阻害剤
|
|
CN101535276B
(zh)
|
2006-10-23 |
2013-08-28 |
赛福伦公司 |
作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物
|
|
US20100137398A1
(en)
*
|
2007-05-04 |
2010-06-03 |
Novartis Ag |
Use of hdac inhibitors for the treatment of gastrointestinal cancers
|
|
CA2693594A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Rigel Pharmaceuticals, Inc. |
Cyclic amine substituted pyrimidinediamines as pkc inhibitors
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
PL2252300T3
(pl)
|
2008-02-22 |
2017-04-28 |
Rigel Pharmaceuticals, Inc. |
Zastosowanie 2,4-pirymidynodiamin do leczenia miażdżycy
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110245156A1
(en)
*
|
2008-12-09 |
2011-10-06 |
Cytokine Pharmasciences, Inc. |
Novel antiviral compounds, compositions, and methods of use
|
|
AT509266B1
(de)
*
|
2009-12-28 |
2014-07-15 |
Univ Wien Tech |
Substituierte pyridine und pyrimidine
|
|
JP2013517273A
(ja)
*
|
2010-01-13 |
2013-05-16 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
化合物および方法
|
|
PT2576541T
(pt)
|
2010-06-04 |
2016-07-08 |
Hoffmann La Roche |
Derivados de aminopirimidina como moduladores de lrrk2
|
|
PH12013500547A1
(en)
|
2010-09-22 |
2013-06-10 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
HRP20172006T1
(hr)
|
2010-11-10 |
2018-02-09 |
Genentech, Inc. |
Derivati pirazol-aminopiridina kao lrrk2-modulatori
|
|
CN112251436A
(zh)
|
2012-01-27 |
2021-01-22 |
比奥马林技术公司 |
治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
CN102952084A
(zh)
*
|
2012-11-15 |
2013-03-06 |
大连九信生物化工科技有限公司 |
一种4，6－二氯－2－甲硫基－5－硝基嘧啶的合成方法
|
|
EP3082819B1
(en)
|
2013-12-20 |
2020-06-17 |
Signal Pharmaceuticals, LLC |
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
|
|
MX386419B
(es)
|
2015-01-06 |
2025-03-18 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
|
EP3939965A1
(en)
|
2015-06-22 |
2022-01-19 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
|
|
WO2017151409A1
(en)
|
2016-02-29 |
2017-09-08 |
University Of Florida Research Foundation, Incorporated |
Chemotherapeutic methods
|
|
HUE064145T2
(hu)
*
|
2016-04-15 |
2024-03-28 |
Epizyme Inc |
Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
|
|
MA47504A
(fr)
|
2017-02-16 |
2019-12-25 |
Arena Pharm Inc |
Composés et méthodes de traitement de l'angiocholite biliaire primitive
|
|
EP3619198B1
(en)
*
|
2017-07-18 |
2020-06-17 |
Lonza Ltd |
Method for preparation of chlorinated s-propylthiobarbituric acid
|
|
WO2019071147A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
ES2987794T3
(es)
|
2018-06-06 |
2024-11-18 |
Arena Pharm Inc |
Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
|
|
MX2021013662A
(es)
|
2019-05-10 |
2022-03-11 |
Deciphera Pharmaceuticals Llc |
Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
|
|
EP3966207B1
(en)
|
2019-05-10 |
2023-11-01 |
Deciphera Pharmaceuticals, LLC |
Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
IL325201A
(en)
|
2019-06-17 |
2026-02-01 |
Deciphera Pharmaceuticals Llc |
Aminopyrimidine amide autophagy inhibitors and methods of using them
|